Drug intelligence / Profile preview

FAV-201

Development stage: Discontinued
Lead developer: Favrille
Modality: Recombinant Proteins and Enzymes, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

FAV-201 is a patient-specific, recombinant immunotherapy designed for the treatment of cutaneous T-cell lymphoma. It is a therapeutic vaccine that utilizes unique proteins found on the surface of malignant T-cells from each individual patient to stimulate an active immune response against those cancer cells. The drug leverages a T-cell receptor-based approach to induce targeted immunity and was developed using insect cell lines to produce Id/KLH immunotherapies, which may enhance dendritic cell interaction and immune activation compared to mammalian cell-derived proteins. FAV-201 was initially developed by Favrille (later MMRGlobal) as part of their portfolio of personalized cancer vaccines[1][2][3][4][7].

Other names: T-cell lymphoma vaccineTorrex

Targets

Id (Tumor-specific idiotype immunoglobulin)

Beyond the preview

Go deeper on FAV-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FAV-201.

Explore the full profile